AU2017249218B2 - Chiral peptides - Google Patents

Chiral peptides Download PDF

Info

Publication number
AU2017249218B2
AU2017249218B2 AU2017249218A AU2017249218A AU2017249218B2 AU 2017249218 B2 AU2017249218 B2 AU 2017249218B2 AU 2017249218 A AU2017249218 A AU 2017249218A AU 2017249218 A AU2017249218 A AU 2017249218A AU 2017249218 B2 AU2017249218 B2 AU 2017249218B2
Authority
AU
Australia
Prior art keywords
amino acid
phe
disease
orn
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017249218A
Other languages
English (en)
Other versions
AU2017249218A1 (en
Inventor
Andrew D. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcuate Therapeutics Inc
Original Assignee
Arcuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcuate Therapeutics Inc filed Critical Arcuate Therapeutics Inc
Publication of AU2017249218A1 publication Critical patent/AU2017249218A1/en
Application granted granted Critical
Publication of AU2017249218B2 publication Critical patent/AU2017249218B2/en
Assigned to ARCUATE THERAPEUTICS, INC. reassignment ARCUATE THERAPEUTICS, INC. Request for Assignment Assignors: CARNOT, LLC
Priority to AU2020260489A priority Critical patent/AU2020260489A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2017249218A 2016-04-11 2017-04-10 Chiral peptides Ceased AU2017249218B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020260489A AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321168P 2016-04-11 2016-04-11
US62/321,168 2016-04-11
PCT/US2017/026869 WO2017180535A1 (en) 2016-04-11 2017-04-10 Chiral peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020260489A Division AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Publications (2)

Publication Number Publication Date
AU2017249218A1 AU2017249218A1 (en) 2018-11-01
AU2017249218B2 true AU2017249218B2 (en) 2020-08-27

Family

ID=60042852

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017249218A Ceased AU2017249218B2 (en) 2016-04-11 2017-04-10 Chiral peptides
AU2020260489A Abandoned AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020260489A Abandoned AU2020260489A1 (en) 2016-04-11 2020-10-29 Chiral peptides

Country Status (7)

Country Link
US (2) US10870678B2 (https=)
EP (1) EP3442990A4 (https=)
JP (1) JP2019523260A (https=)
CN (1) CN109563131A (https=)
AU (2) AU2017249218B2 (https=)
CA (1) CA3020393A1 (https=)
WO (1) WO2017180535A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898653A4 (en) 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
US20210255196A1 (en) * 2020-01-17 2021-08-19 Waters Technologies Corporation Low binding surfaces for peptide mapping
EP4114429A2 (en) * 2020-03-06 2023-01-11 Allegro Pharmaceuticals, LLC Treatments for improving or lessening impairment of mitochondrial function
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
WO2008154373A1 (en) 2007-06-07 2008-12-18 Institute For Hepatitis And Virus Research 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses
CA2701274A1 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
JP5238297B2 (ja) 2008-03-04 2013-07-17 シャープ株式会社 認証方法および入力装置
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2011207432A1 (en) 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
JP6319738B2 (ja) 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
CA2831151A1 (en) 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
AU2012271691A1 (en) 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CA2870200A1 (en) 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
ES2981865T3 (es) * 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20140034183A1 (en) 2012-07-31 2014-02-06 Viz Enterprises, Llc Cap assembly for dispensing a dispensable component and method of making and using the same
AU2013334788A1 (en) 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
CA2919992C (en) 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015023680A1 (en) 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Combination therapy for the treatment of ischemia-reperfusion injury
JP6480921B2 (ja) 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CA2932408A1 (en) 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
JP6626446B2 (ja) 2013-12-27 2019-12-25 ステルス バイオセラピューティックス コープ 薬学的に適切な芳香族カチオン性ペプチド
EP2913287B1 (en) 2014-02-26 2018-01-03 Otis Elevator Company Governor for controlling the speed of a hoisted object relative to a guide member
HK1231493A1 (zh) 2014-03-03 2017-12-22 Stealth Biotherapeutics Corp 药学上相关的芳香族阳离子肽
WO2016004441A1 (en) 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chat R., B & Di Paulo G., "Knockout punch: cardiolipin oxidation in trauma", Nature Neuroscience, 2012. Vol. 15, No. 10, pp, 1325 - 1327 *

Also Published As

Publication number Publication date
JP2019523260A (ja) 2019-08-22
US20190153032A1 (en) 2019-05-23
AU2020260489A1 (en) 2020-11-26
US10870678B2 (en) 2020-12-22
WO2017180535A1 (en) 2017-10-19
EP3442990A4 (en) 2019-12-18
CA3020393A1 (en) 2017-10-19
EP3442990A1 (en) 2019-02-20
US20200407395A1 (en) 2020-12-31
CN109563131A (zh) 2019-04-02
AU2017249218A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
AU2017249218B2 (en) Chiral peptides
DE19544687A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TWI568447B (zh) 具有快速透皮速度的多肽及多肽相關化合物的前藥組合物
CN117624286A (zh) 线粒体靶向肽
TW201117826A (en) Fatty acid niacin conjugates and their uses
JP7082861B2 (ja) 新規な細胞透過性サクシネート化合物
CN102498094A (zh) 胍法辛的前药
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20260055136A1 (en) Mitochondria-targeting peptides
WO2003076391A2 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
EP1483285B1 (de) HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG
DE69908756T2 (de) Matrix-metalloproteinase-inhibitoren
JP2012530764A (ja) メキシレチンのアミノ酸およびペプチドプロドラッグ並びにその使用
CN101395143A (zh) 用于治疗疟疾或aids的氮杂杂环化合物
CN101511816B (zh) 具有改善的生物利用度的氨基异喹啉凝血酶抑制剂
WO2020214518A1 (en) Methods of treating renal conditions using peptides that improve mitochondrial function
US20070238671A1 (en) Isopeptide Gap Junction Modulators
HK1168602A (en) High penetration prodrug compositions of peptides and peptide-related compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ARCUATE THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): CARNOT, LLC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired